Ellen S. de Morrée
Erasmus MC(NL)Erasmus MC Cancer Institute(NL)Erasmus University Rotterdam(NL)
Publications by Year
Research Areas
Prostate Cancer Treatment and Research, Radiopharmaceutical Chemistry and Applications, Cancer Treatment and Pharmacology, Prostate Cancer Diagnosis and Treatment, Cancer, Hypoxia, and Metabolism
Most-Cited Works
- → Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer(2013)204 cited
- → Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer(2014)130 cited
- → Genistein induces breast cancer-associated aromatase and stimulates estrogen-dependent tumor cell growth in in vitro breast cancer model(2011)77 cited
- → Loss of SLCO1B3 drives taxane resistance in prostate cancer(2016)64 cited
- → The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer(2015)63 cited
- → Initial Biopsy Gleason Score as a Predictive Marker for Survival Benefit in Patients with Castration-resistant Prostate Cancer Treated with Docetaxel: Data from the TAX327 Study(2013)58 cited
- → Inter-patient variability in docetaxel pharmacokinetics: A review(2015)46 cited
- → Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered(2016)40 cited
- → Nuclear Eg5 (kinesin spindle protein) expression predicts docetaxel response and prostate cancer aggressiveness(2014)25 cited
- → Effects on androgen receptor nuclear import by docetaxel, cabazitaxel, abiraterone, and enzalutamide: Potential mechanism for cross-resistance in castration-resistant prostate cancer (CRPC).(2013)4 cited